title: Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question.
authors.affiliation: International Drug Development Institute, Louvain-la-Neuve, Belgium2Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Belgium.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Burzykowski
authors.affiliation: International Drug Development Institute, Louvain-la-Neuve, Belgium3Dendrix Research, Sao Paulo, Brazil.
authors.forename: Everardo D
authors.initials: ED
authors.lastname: Saad
authors.affiliation: Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, Belgium4International Drug Development Institute, San Francisco, California.
authors.forename: Marc
authors.initials: M
authors.lastname: Buyse
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases